Novavax Monovalent COVID-19 Vaccine Authorized for Use as Booster Doses in Adults Ages 18 and Older
On October 21, 2022, the Office of MaineCare Services (OMS) sent an announcement that we will cover the Novavax monovalent COVID-19 vaccine booster doses as outlined in an Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA).
OMS has completed the update to our systems, and you may begin to submit claims for these services.
|
Novavax COVID-19 Vaccine Monovalent Booster Dose |
|||
|
Code |
Description |
Effective Date |
MaineCare Rate |
|
91304+ |
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use |
07/13/22 |
$0* |
|
0044A |
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponinbased adjuvant, preservative free, 5 mcg/0.5 mL dosage; booster dose |
10/19/22 |
$36.98 |
|
*Government Supplied Vaccines **Rates for these codes are not yet established +Code previously released 07/13/22 as part of the Novavax COVID-19 vaccine primary series Note: The COVID-19 vaccine administration codes will be added for roster billing |
|||
Providers may visit the Maine CDC Immunization Program Website for up-to-date information on administering and ordering COVID-19 vaccine and booster doses.
If you have questions about the use of Monovalent or Bivalent COVID-19 vaccine booster doses, please contact your Provider Relations Specialist.
Check out our new MaineCare logo! Learn more about this logo on the About Us page of our website.
